Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 3.530 | 3.530 | 0.000 |
Stocks | 96.450 | 96.560 | 0.110 |
Other | 0.020 | 0.020 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 10.394 | 11.126 |
Price to Book | 1.682 | 1.408 |
Price to Sales | 1.153 | 0.886 |
Price to Cash Flow | 6.831 | 5.839 |
Dividend Yield | 3.131 | 4.049 |
5 Years Earnings Growth | 13.693 | 10.091 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 17.050 | 13.343 |
Financial Services | 15.320 | 20.188 |
Industrials | 14.730 | 15.768 |
Consumer Cyclical | 13.070 | 9.451 |
Consumer Defensive | 12.130 | 9.806 |
Basic Materials | 7.370 | 6.752 |
Technology | 7.200 | 5.868 |
Communication Services | 6.290 | 6.791 |
Utilities | 2.880 | 4.167 |
Real Estate | 2.830 | 1.793 |
Energy | 1.110 | 8.086 |
Number of long holdings: 166
Number of short holdings: 2
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Roche Holding Participation | CH0012032048 | 3.68 | 237.10 | +0.98% | |
ASML Holding | NL0010273215 | 3.30 | 853.00 | -0.71% | |
Nestle | CH0038863350 | 3.03 | 96.62 | +1.26% | |
Novo Nordisk A/S Class B | DK0060534915 | 2.64 | - | - | |
Unilever | GB00B10RZP78 | 2.08 | 50.42 | +1.10% | |
GlaxoSmithKline PLC | GB0009252882 | 2.00 | - | - | |
L'Oreal | FR0000120321 | 1.73 | 447.60 | -1.30% | |
Richemont | CH0210483332 | 1.67 | 144.75 | +5.31% | |
Rio Tinto PLC | GB0007188757 | 1.55 | 5,785.0 | +2.41% | |
Vodafone Group PLC | GB00BH4HKS39 | 1.49 | 77.180 | -0.44% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
SEB European Equity B | 247.09M | -8.87 | 5.51 | 8.14 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review